TY - JOUR
T1 - Dendritic cell therapy in combination with interferon-α for the treatment of metastatic renal cell carcinoma
AU - Tatsugami, Katsunori
AU - Eto, Masatoshi
AU - Harano, Masahiko
AU - Hamaguchi, Masumitsu
AU - Miyamoto, Toshihiro
AU - Morisaki, Takashi
AU - Furue, Masutaka
AU - Akashi, Koichi
AU - Naito, Seiji
PY - 2008/8
Y1 - 2008/8
N2 - Objectives: To evaluate the safety and efficacy of dendritic cell (DC) therapy in combination with interferon-α (IFN-α) in patients with advanced renal cell carcinoma. Methods: Seven patients, with progressive disease following IFN-α and interleukin (IL)-2 treatment, were treated with monocyte-derived DC (Mo-DC) and IFN-α between February 2004 and September 2006. They received Mo-DC once a week for 5 weeks and then every 2 weeks either intradermally or intratumorally. IFN-α (5-6 million U) was subcutaneously administered three times a week. Tumor size was evaluated by computed tomography scans before and after the 5th and 10th DC vaccination. A delayed-type hypersensitivity test was performed after the 4th and 5th DC administration for immunological monitoring. Results: Five patients had stable disease while the remaining two patients had progressive disease following 4 months of vaccination. In six patients the time to progression was prolonged in comparison with the previous cytokine treatment. Six patients showed delayed-type hypersensitivity after the 4th or 5th immunization. Three patients developed high fever following DC immunization. Treatment was associated with transient flu-like symptoms. Conclusions: Our data indicate that DC therapy combined with IFN-α is safe and has the potential for prolonging the time to progression in patients with advanced renal cell carcinoma.
AB - Objectives: To evaluate the safety and efficacy of dendritic cell (DC) therapy in combination with interferon-α (IFN-α) in patients with advanced renal cell carcinoma. Methods: Seven patients, with progressive disease following IFN-α and interleukin (IL)-2 treatment, were treated with monocyte-derived DC (Mo-DC) and IFN-α between February 2004 and September 2006. They received Mo-DC once a week for 5 weeks and then every 2 weeks either intradermally or intratumorally. IFN-α (5-6 million U) was subcutaneously administered three times a week. Tumor size was evaluated by computed tomography scans before and after the 5th and 10th DC vaccination. A delayed-type hypersensitivity test was performed after the 4th and 5th DC administration for immunological monitoring. Results: Five patients had stable disease while the remaining two patients had progressive disease following 4 months of vaccination. In six patients the time to progression was prolonged in comparison with the previous cytokine treatment. Six patients showed delayed-type hypersensitivity after the 4th or 5th immunization. Three patients developed high fever following DC immunization. Treatment was associated with transient flu-like symptoms. Conclusions: Our data indicate that DC therapy combined with IFN-α is safe and has the potential for prolonging the time to progression in patients with advanced renal cell carcinoma.
UR - http://www.scopus.com/inward/record.url?scp=49549107094&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=49549107094&partnerID=8YFLogxK
U2 - 10.1111/j.1442-2042.2008.02088.x
DO - 10.1111/j.1442-2042.2008.02088.x
M3 - Article
C2 - 18564205
AN - SCOPUS:49549107094
SN - 0919-8172
VL - 15
SP - 694
EP - 698
JO - International Journal of Urology
JF - International Journal of Urology
IS - 8
ER -
